06.17.15
Heat Biologics, Inc., a clinical stage cancer immunotherapy company, has developed its next-generation combination immunotherapy platform, which combines a pan-antigen T cell priming vaccine and T cell co-stimulator in a single product. This platform, named ComPACT, has been engineered to incorporate various fusion proteins targeting co-stimulatory receptors—OX40, ICOS, 4-1BB—enabling the combination of two important immunotherapy pathways in a single therapy.
“It is now widely recognized in the clinical community that combinations between checkpoint inhibitors, T cell co-stimulators, and vaccines can provide superior benefits to any single modality as monotherapy,” said Taylor Schreiber, vice president of research, Heat Biologics, who led development of ComPACT. “The first challenge in developing these combinations is to systematically identify synergistic pathways from redundant or antagonistic ones. Another challenge is to deploy combination immunotherapies that may limit systemic toxicity and offer an advantageous overall cost structure compared to combining multiple biologic therapies. Heat’s ComPACT therapy is designed to achieve these goals.”
“It is now widely recognized in the clinical community that combinations between checkpoint inhibitors, T cell co-stimulators, and vaccines can provide superior benefits to any single modality as monotherapy,” said Taylor Schreiber, vice president of research, Heat Biologics, who led development of ComPACT. “The first challenge in developing these combinations is to systematically identify synergistic pathways from redundant or antagonistic ones. Another challenge is to deploy combination immunotherapies that may limit systemic toxicity and offer an advantageous overall cost structure compared to combining multiple biologic therapies. Heat’s ComPACT therapy is designed to achieve these goals.”